Sunshine Biopharma to Appear at American Association for Cancer Research Meeting
Company Will Present New Scientific Data at the Meeting April 2-6, 2011 In Orlando, Florida
MONTREAL, April 1 /PRNewswire-FirstCall/ - Sunshine Biopharma, Inc. (OTCBB Ticker Symbol: SBFM) a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that they will be presenting scientific data at the American Association for Cancer Research Meeting April 2-6, 2011 in Orlando Florida.
The DNA repair enzyme Topoisomerase II has been recognized in the oncology field as a clinically important therapeutic target for a variety of cancers. Inhibition of Topoisomerase II activity is essential in the fight against aggressive types of cancer, including multi-resistant breast cancer.
Sunshine Biopharma has developed a new compound, Adva-27a, which acts as a specific inhibitor of Topoisomerase II. The data, which will be presented at the Meeting by the Company's research collaborator, Dr. Susannah Gal of Binghamton University (State University of New York), show that Adva-27a and its derivative, Adva-32a, are significantly more effective at killing aggressive cancer cells than Etoposide, the drug currently in use.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
SOURCE Sunshine Biopharma Inc.
Mr. Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Posted: April 2011